|Videos|September 7, 2021
Emerging Agents for R/R CLL
Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
Advertisement
Episodes in this series
Advertisement
Related to this article
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 and how they may shake up the CLL treatment paradigm.
CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
Advertisement
Advertisement
Trending on OncLive
1
Patient-Level Data Show Extended OS Advantage With DCVax-L vs External Controls in Glioblastoma
2
Zoldonrasib Combinations Show Compelling Antitumor Activity in RAS G12D–Mutant Metastatic PDAC
3
Hematologists Detail Practice-Shaping Data That Emerged at EHA 2026 (VIDEO)
4
Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC
5